Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Net Cash Flow (2017 - 2024)

Solid Biosciences (SLDB) has disclosed Net Cash Flow for 8 consecutive years, with $15.9 million as the latest value for Q4 2024.

  • Quarterly Net Cash Flow fell 36.5% to $15.9 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Dec 2024, up 107.55% year-over-year, with the annual reading at -$20.3 million for FY2025, 420.19% down from the prior year.
  • Net Cash Flow hit $15.9 million in Q4 2024 for Solid Biosciences, up from -$31.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $113.8 million in Q1 2021 to a low of -$90.9 million in Q3 2021.
  • Historically, Net Cash Flow has averaged -$6.3 million across 5 years, with a median of -$9.1 million in 2020.
  • Biggest five-year swings in Net Cash Flow: surged 1035.32% in 2022 and later plummeted 670.37% in 2023.
  • Year by year, Net Cash Flow stood at $1.2 million in 2020, then surged by 651.24% to $9.4 million in 2021, then soared by 1035.32% to $106.4 million in 2022, then crashed by 76.51% to $25.0 million in 2023, then crashed by 36.5% to $15.9 million in 2024.
  • Business Quant data shows Net Cash Flow for SLDB at $15.9 million in Q4 2024, -$31.4 million in Q3 2024, and -$21.6 million in Q2 2024.